Figure 6
Differential protein expression of identified candidates in Tregs. PBMCs were isolated at indicated time points early (< 100 days) and late (> 100 days) after SCT from patients without GVHD (n = 10), with aGVHD/cGVHD (n = 17), and healthy donors (n = 9). (A) Expression values were calculated as a percentage of CD4+CD25hiCD127lo/−Foxp3+ Tregs, and their mean values are presented as bar graphs. (B) Representative overlays from histogram plots are shown for candidates with significant (*P < .05) expression differences. Dashed black lines indicate patients without GVHD; and solid gray lines, patients with aGVHD/cGVHD. Gray shaded areas represent the respective isotype controls. Bold black (gray) numbers indicate the mean fluorescence intensities of CD4+CD25hiCD127lo/−Foxp3+ Tregs in patients without (with) GVHD.

Differential protein expression of identified candidates in Tregs. PBMCs were isolated at indicated time points early (< 100 days) and late (> 100 days) after SCT from patients without GVHD (n = 10), with aGVHD/cGVHD (n = 17), and healthy donors (n = 9). (A) Expression values were calculated as a percentage of CD4+CD25hiCD127lo/−Foxp3+ Tregs, and their mean values are presented as bar graphs. (B) Representative overlays from histogram plots are shown for candidates with significant (*P < .05) expression differences. Dashed black lines indicate patients without GVHD; and solid gray lines, patients with aGVHD/cGVHD. Gray shaded areas represent the respective isotype controls. Bold black (gray) numbers indicate the mean fluorescence intensities of CD4+CD25hiCD127lo/−Foxp3+ Tregs in patients without (with) GVHD.

Close Modal

or Create an Account

Close Modal
Close Modal